$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
使用奈拉宾时应注意哪些事项?
2025-10-19 11:44:20
Check Details
使用奈拉宾的这些事项需要严格注意!
2025-10-19 11:44:20
Check Details
什么?利妥昔单抗也可以治疗免疫性疱病吗?
2025-10-19 11:44:20
Check Details
重磅!达伯华(利妥昔单抗注射液)在中国正式获批上市
2025-10-19 11:44:20
Check Details
FDA授予Liso-Cel优先审评资格,用于二线治疗大B细胞淋巴瘤(LBCL)
2025-10-19 11:44:20
Check Details
杜韦利西布联合用药治疗淋巴瘤疗效和安全性!
2025-10-19 11:44:20
Check Details
利妥昔单抗Ristova治疗效果好不好?治疗多久能见效
2025-10-19 11:44:20
Check Details
伊布替尼+利妥昔单抗一线治疗惰性套细胞淋巴瘤缓解率高
2025-10-19 11:44:20
Check Details
淋巴瘤药物——苯达莫司汀(Bendamustine)
2025-10-19 11:44:20
Check Details
总缓解率97%!阿卡替尼一线治疗白血病长期数据公布
2025-10-19 11:44:20
Check Details
阿卡替尼获批,试验数据中总体缓解率可观
2025-10-19 11:44:20
Check Details
利妥昔单抗可以用医保购买吗?治疗期间需要注意什么?
2025-10-19 11:44:20
Check Details
1
2
...
1265
1266
1267
1268
1269
1270
1271
...
4157
4158
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Tivozanib: A Next-Generation Highly Selective VEGFR-Targeted Therapy Explained
2
Capmatinib Clinical Guide: Drug Comparisons, Treatment Strategies, and Combination Therapy Prospects
3
Pralsetinib Clinical Guide: Discontinuation Principles, Drug Comparisons, and Treatment Strategies
4
Dabrafenib Clinical Guide: Indications, Combination Strategies, and BRAF Inhibitor Comparisons
5
Cabozantinib Capsules: A Multi-Targeted Therapy for Progressive Medullary Thyroid Cancer
6
Lorlatinib: Mechanism, Advantages, and Key Considerations of Third-Generation ALK Inhibitor Therapy in ALK-Positive NSCLC
7
Pemigatinib Side Effects Explained: Managing Adverse Reactions of FGFR-Targeted Therapy in Cholangiocarcinoma
8
Selpercatinib: Before or After Meals? A Complete Guide to RET-Targeted Therapy Administration
9
Mitotane for Adrenocortical Carcinoma: Dosing Guidelines and Therapeutic Drug Monitoring
10
Leflunomide and Ocular Adverse Effects: Risk Awareness and Clinical Guidance
11
Clinical Management of Acquired Resistance to Garsorasib (KRAS G12C Inhibitor)
12
Chemical Structure of Capivasertib: A Novel AKT Inhibitor